Trevena, Inc.
US ˙ OTCPK ˙ US89532E2081

Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael R Dougherty. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael R Dougherty has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:IDRA / Idera Pharmaceuticals, Inc. Director 375,155
US:MRNS / Marinus Pharmaceuticals, Inc. Director 12,375
US:TRVN / Trevena, Inc. Director 68,577
US:FMI / Foundation Medicine, Inc. Director 0
US:VXRT / Vaxart, Inc. Director 105,000
US:CEMP / Cempra, Inc. Director 15,000
Executive Chairman, Director 0
US:VPHM / Shire Viropharma Inc Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael R Dougherty. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases TRVN / Trevena, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TRVN / Trevena, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2014-12-10 TRVN DOUGHERTY MICHAEL R 7,000 4.0000 280 100.0000 28,000 282 332.5 65,100 232.50

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRVN / Trevena, Inc. Insider Trades
Insider Sales TRVN / Trevena, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TRVN / Trevena, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRVN / Trevena, Inc. Insider Trades
Insider Purchases VXRT / Vaxart, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TRVN / Trevena, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VXRT / Vaxart, Inc. Insider Trades
Insider Sales VXRT / Vaxart, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TRVN / Trevena, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VXRT / Vaxart, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Michael R Dougherty as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-01-12 2023-01-11 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 33,523 375,155 9.81 0.44 14,750 165,068
2022-10-05 2022-10-03 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 58,516 341,632 20.67 0.37 21,938 128,078
2022-07-06 2022-07-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 50,086 283,116 21.49 0.44 21,938 124,005
2022-04-05 2022-04-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 41,155 233,030 21.45 0.54 22,018 124,671
2022-02-07 2022-02-04 4 MRNS MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 12,375 12,375
2022-02-07 2022-02-04 4 MRNS MARINUS PHARMACEUTICALS INC
Common Stock
A - Award 2,750 3,312 489.32
2022-01-05 2022-01-03 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 37,062 191,875 23.94 0.59 21,867 113,206
2021-10-04 2021-10-04 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 21,229 154,813 15.89 1.03 21,866 159,457
2021-06-10 2021-06-08 4 IDRA IDERA PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 26,000 26,000
2021-06-03 2021-06-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
P - Purchase 85,000 133,584 174.95 1.19 101,150 158,965
2021-06-02 2021-05-28 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 68,577 68,577
2021-04-05 2021-04-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 10,939 48,584 29.06 1.32 14,439 64,131
2021-01-19 2021-01-15 4 MRNS MARINUS PHARMACEUTICALS INC
Stock option (right to buy)
A - Award 16,500 16,500
2021-01-06 2021-01-04 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 3,515 37,645 10.30 4.02 14,130 151,333
2020-10-05 2020-10-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 5,722 34,130 20.14 2.25 12,874 76,792
2020-07-02 2020-07-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 7,193 28,408 33.91 1.79 12,875 50,850
2020-05-19 2020-05-12 4 IDRA IDERA PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 11,500 11,500
2020-05-15 2020-05-13 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 64,103 64,103
2020-04-03 2020-04-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 10,059 21,215 90.17 1.28 12,876 27,155
2020-01-10 2020-01-08 4 MRNS MARINUS PHARMACEUTICALS INC
Stock option (right to buy)
A - Award 100,000 100,000
2020-01-06 2020-01-02 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 7,037 11,156 170.84 1.85 13,018 20,639
2019-10-02 2019-10-01 4 IDRA IDERA PHARMACEUTICALS, INC.
Common Stock
A - Award 4,119 4,119 2.67 10,998 10,998
2019-06-06 2019-06-04 4 IDRA IDERA PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 11,500 11,500
2019-05-16 2019-05-16 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 30,000 30,000
2019-04-10 2019-04-08 4 IDRA IDERA PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 23,000 23,000
2019-02-28 2019-02-26 4 MRNS MARINUS PHARMACEUTICALS INC
Stock option (right to buy)
A - Award 35,000 35,000
2018-08-02 2018-07-31 4 FMI Foundation Medicine, Inc.
Common Stock
J - Other -12,669 0 -100.00 137.00 -1,735,653
2018-08-02 2018-07-31 4 FMI Foundation Medicine, Inc.
Common Stock
U - Other -12,120 12,669 -48.89 137.00 -1,660,440 1,735,653
2018-05-17 2018-05-16 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 30,000 30,000
2017-12-08 2017-12-06 4 MRNS MARINUS PHARMACEUTICALS INC
Stock option (right to buy)
A - Award 35,000 35,000
2017-06-22 2017-06-20 4 FMI Foundation Medicine, Inc.
Common Stock
A - Award 5,786 24,789 30.45 40.05 231,729 992,799
2017-06-06 2017-05-17 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 15,000 15,000
2017-05-22 2017-05-18 4 AVIR Aviragen Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 20,000 105,000 23.53 0.49 9,800 51,450
2017-02-01 3 NASDAQMRNS MARINUS PHARMACEUTICALS INC
Restricted stock
18,000
2017-02-01 3 NASDAQMRNS MARINUS PHARMACEUTICALS INC
Restricted stock
18,000
2017-01-05 2017-01-03 4 CEMP CEMPRA, INC.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2016-10-28 2016-10-26 4 FMI Foundation Medicine, Inc.
Common Stock
A - Award 19,003 19,003 23.55 447,521 447,521
2016-10-28 3 FMI Foundation Medicine, Inc.
Common Stock
0
2016-07-12 2016-07-12 4 CPXX Celator Pharmaceuticals Inc
Stock Option (right to buy)
D - Sale to Issuer -500,000 0 -100.00 28.07 -14,035,000
2016-07-12 2016-07-12 4 CPXX Celator Pharmaceuticals Inc
Stock Option (right to buy)
D - Sale to Issuer -22,000 0 -100.00 27.65 -608,300
2016-07-12 2016-07-12 4 CPXX Celator Pharmaceuticals Inc
Stock Option (right to buy)
D - Sale to Issuer -20,600 0 -100.00 27.60 -568,560
2016-07-12 2016-07-12 4 CPXX Celator Pharmaceuticals Inc
Stock Option (right to buy)
D - Sale to Issuer -14,000 0 -100.00 27.45 -384,300
2016-07-12 2016-07-12 4 CPXX Celator Pharmaceuticals Inc
Stock Option (right to buy)
D - Sale to Issuer -28,000 0 -100.00 27.13 -759,752
2016-07-12 2016-07-12 4 CPXX Celator Pharmaceuticals Inc
Common Stock
D - Sale to Issuer -20,000 0 -100.00 30.25 -605,000
2016-07-12 2016-01-27 4 CPXX Celator Pharmaceuticals Inc
Stock Option (right to buy)
D - Sale to Issuer -17,457 0 -100.00 28.93 -505,031
2016-07-12 2016-01-27 4 CPXX Celator Pharmaceuticals Inc
Stock Option (right to buy)
D - Sale to Issuer -75,000 0 -100.00 28.93 -2,169,750
2016-05-19 2016-05-18 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 15,000 15,000
2016-05-13 2016-05-12 4 AVIR Aviragen Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 20,000 20,000 1.50 30,000 30,000
2016-01-29 2016-01-27 4 CPXX Celator Pharmaceuticals Inc
Stock Option, Right to Buy
A - Award 17,457 17,457
2016-01-29 2016-01-27 4 CPXX Celator Pharmaceuticals Inc
Stock Option, Right to Buy
A - Award 75,000 75,000
2016-01-05 2016-01-01 4 CEMP CEMPRA, INC.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2015-10-27 2015-10-26 4 CEMP CEMPRA, INC.
Common Stock
P - Purchase 2,000 2,000 18.45 36,896 36,896
2015-08-24 2015-08-20 4 CPXX Celator Pharmaceuticals Inc
Stock Option (right to buy)
A - Award 500,000 500,000
2015-08-13 2015-08-11 4 BOTA Biota Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 5,000 5,000
2015-06-15 2015-06-11 4 CPXX Celator Pharmaceuticals Inc
Stock Option (right to buy)
A - Award 22,000 22,000
2015-05-21 2015-05-20 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 8,870 8,870
2015-05-14 2015-05-12 4 BOTA Biota Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2015-01-02 2015-01-01 4 CEMP CEMPRA, INC.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2014-12-10 2014-12-10 4 TRVN TREVENA INC
Common Stock
P - Purchase 7,000 7,000 4.00 28,000 28,000
2014-11-20 2014-11-18 4 CPXX Celator Pharmaceuticals Inc
Common Stock
P - Purchase 20,000 20,000 2.15 42,940 42,940
2014-08-15 2014-08-14 4 CPXX Celator Pharmaceuticals Inc
Stock Option (right to buy)
A - Award 20,600 20,600
2014-06-16 2014-06-12 4 CPXX Celator Pharmaceuticals Inc
Stock Option (right to buy)
A - Award 14,000 14,000
2014-05-20 2014-05-15 4 BOTA Biota Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2014-05-15 2014-05-14 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 8,870 8,870
2014-01-30 3 TRVN TREVENA INC
Common Stock
0
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Restricted Stock Units
D - Sale to Issuer -4,500 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
D - Sale to Issuer -10,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
D - Sale to Issuer -10,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
D - Sale to Issuer -10,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Common Stock
U - Other -20,812 0 -100.00 50.00 -1,040,600
2014-01-10 2014-01-08 4 CEMP CEMPRA, INC.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
M - Exercise -10,000 0 -100.00
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Common Stock
F - Taxes -688 20,812 -3.20 49.74 -34,221 1,035,189
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 10,000 21,500 86.96 3.42 34,200 73,530
2013-07-24 2013-07-23 4 NONE Celator Pharmaceuticals Inc
Stock Option (right to buy)
A - Award 28,000 28,000
2013-06-04 2013-06-03 4 CEMP CEMPRA, INC.
Stock Option (Right to Buy)
A - Award 25,000 25,000
2013-05-28 3 CEMP CEMPRA, INC.
No securities beneficially owned
0
2013-05-03 2013-05-01 4 BOTA Biota Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 30,000 30,000
2013-02-25 2013-02-22 4 VPHM VIROPHARMA INC
Stock Option (Right to Buy)
A - Award 15,000 15,000
2013-02-25 2013-02-22 4 VPHM VIROPHARMA INC
Restricted Stock Units
A - Award 4,500 4,500
2013-02-25 2013-02-22 4 VPHM VIROPHARMA INC
Common Stock
A - Award 4,500 11,500 64.29
2012-12-05 2012-12-03 4 VPHM VIROPHARMA INC
Common Stock
P - Purchase 2,500 7,000 55.56 25.07 62,675 175,490
2012-02-28 2012-02-24 4 VPHM VIROPHARMA INC
Restricted Stock Units
A - Award 4,500 4,500
2012-02-28 2012-02-24 4 VPHM VIROPHARMA INC
Non-qualified Stock Option (Right to Buy)
A - Award 15,000 15,000
2012-02-28 2012-02-21 4 VPHM VIROPHARMA INC
Common Stock
A - Award 4,500 4,500
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)